Fennec Pharmaceuticals (FENC) Net Income towards Common Stockholders (2010 - 2025)
Fennec Pharmaceuticals posted quarterly Net Income towards Common Stockholders of $2.1 million for Q4 2025, up 242.11% year-on-year from $623492.3 in Q4 2024, and up 442.38% on a QoQ basis from -$623000.0 in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of Net Income towards Common Stockholders data on file, last reported at $2.1 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 242.11% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2025 stood at -$2.8 million (down 1651.93% YoY), and the FY2025 full-year result was -$9.7 million, down 180.8% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at $2.1 million, up from -$623000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $12.9 million in Q1 2024 and bottomed at -$8.0 million in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is -$4.1 million (2021), against an average of -$3.0 million.
- Peak annual rise in Net Income towards Common Stockholders reached 316.58% in 2024, while the deepest fall reached 222.47% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.3 million in 2021, then tumbled by 58.04% to -$6.7 million in 2022, then surged by 61.08% to -$2.6 million in 2023, then soared by 42.67% to -$1.5 million in 2024, then jumped by 242.11% to $2.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at $2.1 million (Q4 2025), -$623000.0 (Q3 2025), and -$3.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 2.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.13 Mn |
| Sep 30, 2025 | -623,000.00 |
| Jun 30, 2025 | -3.16 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Sep 30, 2024 | -5.71 Mn |
| Jun 30, 2024 | -5.51 Mn |
| Mar 31, 2024 | 12.91 Mn |
| Dec 31, 2023 | -2.62 Mn |
| Sep 30, 2023 | -1.77 Mn |
| Jun 30, 2023 | -5.38 Mn |
| Mar 31, 2023 | -5.96 Mn |
| Dec 31, 2022 | -6.73 Mn |
| Sep 30, 2022 | -7.99 Mn |
| Jun 30, 2022 | -5.06 Mn |
| Mar 31, 2022 | -3.60 Mn |
| Dec 31, 2021 | -4.26 Mn |
| Sep 30, 2021 | -4.22 Mn |
| Jun 30, 2021 | -3.92 Mn |
| Mar 31, 2021 | -4.91 Mn |
| Dec 31, 2020 | -3.33 Mn |
| Sep 30, 2020 | -5.84 Mn |
| Jun 30, 2020 | -4.83 Mn |
| Mar 31, 2020 | -3.80 Mn |
| Dec 31, 2019 | -3.58 Mn |
| Sep 30, 2019 | -1.79 Mn |
| Jun 30, 2019 | -4.70 Mn |
| Mar 31, 2019 | -2.61 Mn |
| Dec 31, 2018 | -2.99 Mn |
| Sep 30, 2018 | -2.75 Mn |
| Jun 30, 2018 | -2.59 Mn |
| Mar 31, 2018 | -1.73 Mn |
| Dec 31, 2017 | -2.49 Mn |
| Sep 30, 2017 | -2.17 Mn |
| Jun 30, 2017 | -1.47 Mn |
| Mar 31, 2017 | -768,000.00 |
| Dec 31, 2016 | -1.14 Mn |
| Sep 30, 2016 | -561,000.00 |
| Jun 30, 2016 | -704,000.00 |
| Mar 31, 2016 | -454,000.00 |
| Dec 31, 2015 | -551,000.00 |
| Sep 30, 2015 | -337,000.00 |
| Jun 30, 2015 | -558,000.00 |
| Mar 31, 2015 | -451,000.00 |
| Dec 31, 2014 | -790,000.00 |
| Sep 30, 2014 | -619,000.00 |
| Jun 30, 2014 | -931,000.00 |
| Mar 31, 2014 | -539,000.00 |
| Dec 31, 2013 | -417,000.00 |
| Sep 30, 2013 | -51,000.00 |
| Jun 30, 2013 | -930,000.00 |
| Mar 31, 2013 | -535,000.00 |
| Dec 31, 2012 | -1.11 Mn |
| Sep 30, 2012 | -625,000.00 |
| Jun 30, 2012 | -1.25 Mn |
| Mar 31, 2012 | -608,000.00 |
| Dec 31, 2011 | -888,000.00 |
| Sep 30, 2011 | -923,000.00 |
| Jun 30, 2011 | -573,000.00 |
| Mar 31, 2011 | -1.01 Mn |
| Dec 31, 2010 | -805,000.00 |
| Sep 30, 2010 | -904,000.00 |
| Jun 30, 2010 | -2.50 Mn |